PTC Therapeutics (PTCT) Gains as Sarepta's Eteplirsen Approved

September 19, 2016 9:54 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

PTC Therapeutics (NASDAQ: PTCT) gains as Sarepta's eteplirsen gains FDA accelerated approval.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Momentum Movers, Trader Talk

Add Your Comment